ArticleCancer immunology, immunotherapy : CII2008
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.Journal for immunotherapy of cancer · 2023Article
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies.Nature reviews. Clinical oncology · 2021Review
- The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy.Molecular therapy. Methods & clinical development · 2021Article
- Advances in engineering local drug delivery systems for cancer immunotherapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.Frontiers in immunology · 2020Review
- Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade.RSC advances · 2019Review
- Optimization of a 2A self-cleaving peptide-based multigene expression system for efficient expression of upstream and downstream genes in silkworm.Molecular genetics and genomics : MGG · 2019Article
- Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors.Cancer discovery · 2019Article
- Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors.Frontiers in oncology · 2019Article
- Expression of Cholesterol Hydroxylase/Lyase System Proteins in Yeast S. cerevisiae Cells as a Self-Processing Polyprotein.Molecular biotechnology · 2017Article
- Targeting Melanoma with Cancer-Killing Viruses.The open virology journal · 2017Article
- In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.Molecular oncology · 2015Review
- 2A self-cleaving peptide-based multi-gene expression system in the silkworm Bombyx mori.Scientific reports · 2015Article
- Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells.mAbs · 2015Article
- Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.Cancer gene therapy · 2014Article
- Intratumoral immunization: a new paradigm for cancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.Oncoimmunology · 2014Article
- Local immunomodulation for cancer therapy: Providing treatment where needed.Oncoimmunology · 2013Article
- Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Promising anti-tumor responses have been observed in the clinic using monoclonal antibodies (mAbs) that block immune checkpoints. One concern with these therapeutic agents remains the potential induction of immune breakthrough events (IBEs) resulting from the disruption of T cell homeostasis or the breaking of tolerance to self antigens. As an approach to maintaining anti-tumor responses but decreasing the likelihood of these events, the local expression of a mAb in combination with a GM-CSF-secreting cancer immunotherapy was evaluated. Using anti-cytotoxic T lymphocyte antigen (CTLA)-4 as a model antibody to test this hypothesis, tumor cell lines were generated that expressed the full-length mAb in addition to GM-CSF. Evaluation of these cell lines in two therapeutic tumor models revealed that local, cell-mediated delivery of anti-CTLA-4 from a GM-CSF-secreting tumor cell immunotherapy activated potent anti-tumor responses and prolonged overall survival at significantly lower serum mAb levels in the host. Furthermore, lowering the systemic exposure of the host to the immune modulatory mAb correlated with reduced evidence of systemic autoimmunity. This approach has broad utility for the delivery of mAbs or proteins locally from cellular immunotherapies to minimize IBEs while retaining the potent therapeutic effects of such combination treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.